Annovis Bio, Inc. Cash and Restricted Cash
Annovis Bio, Inc. (ANVS) had Cash and Restricted Cash of $18.73 million as of 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents · last filed 2026-08-14
- 2026-06-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $18.73M.
- 2026-03-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $14.22M.
- 2025-12-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $19.53M.
- 2025-09-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $15.29M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents |
|---|---|
| 2026-06-30 | $18.73M 10-Q · filed 2026-08-14 |
| 2026-03-31 | $14.22M 10-Q · filed 2026-05-15 |
| 2025-12-31 | $19.53M 10-Q · filed 2026-08-14 |
| 2025-09-30 | $15.29M 10-Q · filed 2025-11-12 |
| 2025-06-30 | $17.13M 10-Q · filed 2026-08-14 |
| 2025-03-31 | $22.24M 10-Q · filed 2026-05-15 |
| 2024-12-31 | $10.55M 10-Q · filed 2026-08-14 |
| 2024-09-30 | $12.64M 10-Q · filed 2025-11-12 |
| 2024-06-30 | $4.00M 10-Q · filed 2025-08-12 |
| 2024-03-31 | $3.14M 10-Q · filed 2025-05-13 |
| 2023-12-31 | $5.75M 10-K · filed 2026-03-13 |
| 2023-09-30 | $6.35M 10-Q · filed 2024-11-08 |
| 2023-06-30 | $15.72M 10-Q · filed 2024-08-14 |
| 2023-03-31 | $16.76M 10-Q · filed 2024-05-10 |
| 2022-12-31 | $28.38M 10-K · filed 2025-03-21 |
| 2022-09-30 | $31.99M 10-Q · filed 2023-11-08 |
| 2022-06-30 | $35.97M 10-Q · filed 2023-08-14 |
| 2022-03-31 | $42.67M 10-Q · filed 2023-05-10 |
| 2021-12-31 | $45.69M 10-K · filed 2024-03-29 |
| 2021-09-30 | $47.46M 10-Q · filed 2022-11-08 |
| 2021-06-30 | $49.22M 10-Q · filed 2022-08-08 |
| 2021-03-31 | $5.60M 10-Q · filed 2022-05-04 |
| 2020-12-31 | $8.07M 10-K · filed 2023-03-31 |
| 2020-09-30 | $8.84M 10-Q · filed 2021-11-03 |
| 2020-06-30 | $9.76M 10-Q · filed 2021-07-28 |
| 2020-03-31 | $11.12M 10-Q · filed 2021-05-06 |
| 2019-12-31 | $1.86K 10-K · filed 2022-03-02 |
| 2019-09-30 | $56.25K 10-Q · filed 2020-11-04 |
| 2019-06-30 | $104.55K 10-Q · filed 2020-07-29 |
| 2019-03-31 | $336.57K 10-Q · filed 2020-05-05 |
| 2018-12-31 | $35.31K 10-K · filed 2021-03-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| HERON THERAPEUTICS, INC. /DE/ (HRTX) | United States | $0.055B | -2.38 |
| Clene Inc. (CLNN) | United States | $0.054B | -1.99 |
| NOMAD POWER SOLUTIONS, INC. (NMAD) | United States | $0.058B | |
| Serina Therapeutics, Inc. (SER) | United States | $0.054B | -2.35 |
| Boundless Bio, Inc. (BOLD) | United States | $0.059B | -0.88 |
| TALPHERA, INC. (TLPH) | United States | $0.060B | |
| CalciMedica, Inc. (CALC) | United States | $0.061B | -1.42 |
| Xilio Therapeutics, Inc. (XLO) | United States | $0.052B | |
| Skye Bioscience, Inc. (SKYE) | United States | $0.061B | -0.48 |
| Rein Therapeutics, Inc. (RNTX) | United States | $0.063B | -1.76 |